QUÉBEC CITY, May 18, 2016 /CNW Telbec/ - TSO3 Inc. (TSX: TOS), an innovator in sterilization technology for medical devices in healthcare settings, announced today that a peer-reviewed paper describing the Company's STERIZONE® VP4 Sterilizer has been accepted for publication in the Canadian Journal of Infection Control (CJIC). The paper entitled "The First Dual-Sterilant Low-Temperature Sterilization System" will appear in an upcoming issue of the publication.
The paper, co-authored by Dr Sylvie Dufresne and Dr Thomas Richards, discusses the unique chemistry of the STERIZONE® VP4 Sterilizer, the first commercially available dual-sterilant low-temperature sterilization device. In particular, the paper highlights TSO3's innovative approach of controlling the sterilization process by use of pressure rather than the traditional sterilization method of sterilant dose and time. The paper also discusses how the device was validated including half-cycle, simulated-use, and "in-use" clinical testing.
"We are very pleased to see this peer-reviewed paper accepted and look forward to its publication in this respected journal in the field of infection prevention and control," stated R.M. (Ric) Rumble TSO3's president and CEO. "This paper follows a recent poster presentation by the Company at the IAHCSMM conference in San Antonio, Texas last April and demonstrates TSO3's commitment to advancing the science of sterilization."
About the STERIZONE® VP4 low temperature sterilizer
The STERIZONE® VP4 Sterilizer developed by TSO3 is a dual sterilant, low temperature sterilization system that utilizes vaporized hydrogen peroxide (H2O2) and ozone. Its single cycle can sterilize a large number and wide range of compatible devices, thereby allowing for a cost effective and error-free sterilization process. TSO3's unique Dynamic Sterilant Delivery SystemTM automatically adjusts the quantity of injected sterilant based on the load composition, weight and temperature. With its large 75 lb load capacity and a short cycle time, the STERIZONE® VP4 Sterilizer can enhance throughput and lower sterilization cost. The STERIZONE® VP4 Sterilizer was cleared for commercialization in the United States in December 2014.
More information about the STERIZONE® VP4 Sterilizer is available through TSO3's website, under the Products section: http://www.tso3.com/en/products/sterizone-vp4/
Founded in 1998, TSO3 (TSX: TOS) is committed to improving the standard of healthcare sterile reprocessing by providing breakthrough sterilization systems, related consumable supplies and accessories for heat-sensitive medical devices. TSO3 designs products for sterile processing areas in the hospital environment that offer an advantageous replacement solution to other low-temperature sterilization processes currently used in hospitals. It also offers services related to the maintenance of sterilization equipment and compatibility testing of medical devices with such processes. For more information about TSO3, visit the company's web site at www.tso3.com.
The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities, in any jurisdiction in which such offer, solicitation or sale would be unlawful.
The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.
SOURCE TSO3 Inc.
For further information: Company Contacts: TSO3 Inc., R.M. (Ric) Rumble, President and CEO, Tel: 418 651-0003, Email: firstname.lastname@example.org; TSO3 Inc., Glen Kayll, CFO, Tel: 418 651-0003, Email: email@example.com; Investor Relations: Liolios Group, Inc., Ron Both, Tel: 949 574-3860, TOS@liolios.com; Renmark Financial Communications Inc., Barry Mire, Tel: 416 644-2020 or 514 939-3989, firstname.lastname@example.org